Publications by authors named "Ulrika Tehler"

Claim this Profile
A
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.
Anna Lundahl, Rod Hughes, Joachim Almquist, David Close, Jukka Mäenpää, Ulrika Tehler

Br J Clin Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products.
Ben Forbes, Per Bäckman, Antonio Cabal, Andy Clark, Carsten Ehrhardt, Ulrika Tehler

Mol Pharm· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
World-wide-working-web: How to be successful on global teams.
Marianna Yanez Arteta, Liping Zhou, Ulrika Tehler, Annette Bak

J Pharm Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.
Jayne E Hastedt, Per Bäckman, Antonio Cabal, Andy Clark, Carsten Ehrhardt, Ulrika Tehler

Mol Pharm· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model.
Irès van der Zwaan, Frans Franek, Rebecca Fransson, Ulrika Tehler, Göran Frenning

Mol Pharm· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.
Cecilia Kristensson, Annika Åstrand, Scott Donaldson, Ron Goldwater, Raolat Abdulai, Ulrika Tehler

J Cyst Fibros· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.
Jayne E Hastedt, Per Bäckman, Antonio Cabal, Andy Clark, Carsten Ehrhardt, Ulrika Tehler

Mol Pharm· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes.
Per Bäckman, Antonio Cabal, Andy Clark, Carsten Ehrhardt, Ben Forbes, Ulrika Tehler

Mol Pharm· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.
Susanne Prothon, Magnus Aurivillius, Ulrika Tehler, Ulf G Eriksson, Ajay Aggarwal

Drug Des Devel Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyaluronic Acid Hydrogels for Controlled Pulmonary Drug Delivery-A Particle Engineering Approach.
Dariush Nikjoo, Irès van der Zwaan, Mikael Brülls, Ulrika Tehler, Göran Frenning

Pharmaceutics· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs.
Pär Ewing, Steven Oag, Anders Lundqvist, Stina Stomilovic, Ida Stellert, Ulrika Tehler

J Aerosol Med Pulm Drug Deliv· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.
Göran Frenning, Irès van der Zwaan, Frans Franek, Rebecca Fransson, Ulrika Tehler

Mol Pharm· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers.
Susanne Prothon, Ulrika Wählby Hamrén, Ulrika Tehler, Esther Yoon, Henrik Forsman

Drug Des Devel Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data.
Koustav Ganguly, Ulrika Carlander, Estella Dg Garessus, Markus Fridén, Ulf G Eriksson, Ulrika Tehler

Crit Rev Toxicol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ranking in Vitro Dissolution of Inhaled Micronized Drug Powders including a Candidate Drug with Two Different Particle Sizes.
Frans Franek, Rebecca Fransson, Helena Thörn, Per Bäckman, Patrik U Andersson, Ulrika Tehler

Mol Pharm· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.
Martin Hemmerling, Stinabritt Nilsson, Karl Edman, Stefan Eirefelt, Wayne Russell, Ulrika Tehler

J Med Chem· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition.
Per Bäckman, Ulrika Tehler, Bo Olsson

J Aerosol Med Pulm Drug Deliv· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice.
Ulrika Tehler, Jonas H Fagerberg, Richard Svensson, Mats Larhed, Per Artursson

J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme.
Ulrika Tehler, Cara H Nelson, Larryn W Peterson, Chester J Provoda, John M Hilfinger

Antiviral Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis